Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/38667
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Delbridge L.M.D. | en |
dc.contributor.author | Ip W.T.K. | en |
dc.contributor.author | Chandramouli C. | en |
dc.contributor.author | Smith J.A. | en |
dc.contributor.author | McLennan P.L. | en |
dc.contributor.author | Pepe S. | en |
dc.date.accessioned | 2021-05-14T13:11:58Z | en |
dc.date.available | 2021-05-14T13:11:58Z | en |
dc.date.copyright | 2017 | en |
dc.date.created | 20170707 | en |
dc.date.issued | 2017-07-07 | en |
dc.identifier.citation | Heart Lung and Circulation. 26 (8) (pp 846-855), 2017. Date of Publication: August 2017. | en |
dc.identifier.issn | 1443-9506 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/38667 | en |
dc.description.abstract | Background Epidemiological studies and randomised clinical trials (RCTs) report disparate findings in relation to omega-3 polyunsaturated fatty acids (n-3 PUFA) benefit for cardiac patients. With RCTs interpretation is potentially confounded by background n-3 PUFA intake. The goal of this pilot, small cohort, pre-surgical supplementation study was to evaluate postoperative atrial fibrillation (AF) and cardiac molecular expression profiles employing two data analysis approaches - by treatment randomisation and by stratification using measured n-3 PUFA. Methods Patients (n = 20) received 3 g/day of fish or placebo oil (FO vs PO) in a double blind randomised protocol prior to elective coronary artery graft and valve surgery. Groups were matched for age, gender, and mean treatment duration (~20 days). Resected atrial myocardium was sampled for assay of viability metabolic markers, and blood obtained for erythrocyte membrane lipid measurement. Results There was substantial overlap of cell membrane n-3 PUFA content across PO and FO groups, and no group treatment effects on AF incidence or myocardial molecular marker levels were detected. In contrast, data stratification using membrane n-3 PUFA content (at 8% total membrane lipid) achieved significant separation of patients (by n-6:n-3 PUFA ratio), a significant differential cardiac expression of the marker peroxisomal proliferator-activated receptor, but no difference in AF incidence. Conclusions This small n-3 PUFA case study demonstrates that the same cohort may yield differing findings when evaluated using randomisation or stratification approaches based on direct molecular measures in cell membranes.Copyright © 2017 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ) | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Elsevier Ltd | en |
dc.relation.ispartof | Heart Lung and Circulation | en |
dc.title | A Small Cohort Omega-3 PUFA Supplement Study: Implications of Stratifying According to Lipid Membrane Incorporation in Cardiac Surgical Patients. | en |
dc.type | Article | en |
dc.identifier.affiliation | Cardiothoracic Surgery | - |
dc.type.studyortrial | Randomised controlled trial | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.hlc.2016.12.007 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.orcid | McLennan, Peter L.; ORCID: http://orcid.org/0000-0003-0252-8039 | en |
dc.identifier.pubmedid | 28237535 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28237535] | en |
dc.identifier.source | 614529437 | en |
dc.identifier.institution | (Ip, Chandramouli, Delbridge) Cardiac Phenomics Laboratory, Department of Physiology, University of Melbourne, Melbourne, Vic, Australia (Smith) Department of Cardiothoracic Surgery, Monash Health, Monash University, Melbourne, Vic, Australia (Smith) Department of Surgery, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Vic, Australia (McLennan) Graduate School of Medicine, Centre for Human Applied Physiology, University of Wollongong, Sydney, NSW, Australia (Pepe) Murdoch Children's Research Institute, Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Melbourne, Vic, Australia | en |
dc.description.address | S. Pepe, Department of Cardiology, Royal Children's Hospital, 50 Flemington Road, Parkville, VIC 3052, Australia. E-mail: salvatore.pepe@mcri.edu.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2017 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Atrial fibrillation Bax Bcl2 Omega-3 polyunsaturated fatty acids (PUFA) Peroxisomal proliferator-activated receptor (PPAR) | en |
dc.identifier.authoremail | Pepe S.; salvatore.pepe@mcri.edu.au | en |
dc.description.grant | Organization: (NHMRC) *National Health and Medical Research Council* Country: Australia | en |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairetype | Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
crisitem.author.dept | Cardiothoracic Surgery | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.